论文部分内容阅读
目的为提高对黏膜相关淋巴组织淋巴瘤（ＭＡＬＴ淋巴瘤）临床特征的认识。方法经我院确诊的ＭＡＬＴ淋巴瘤２４例，进行回顾性的临床分析研究。结果按原发部位可分为胃肠（ＧＩ）和非胃肠（ＮＯＮＧＩ）两组。ＧＩ组１８例（７５０％），ＮＯＮＧＩ组６例（２５０％），后者包括涎腺３例、肺２例和膀胱１例。手术治疗２１例，其中单用手术治疗１３例，术后合用化、放疗７例，合用放疗１例。单用化疗３例。随访１７例，失访７例，随访率为７０．８％。生存期４～１２１个月，平均３３个月，中位数１９个月。１７例随访病人中１６例已存活１～１０年，其中存活１年以上者占５８．８％、＞３年以上者占３５．３％、５年以上者占２９．４％、１０年以上者占５．９％。对临床分期和治疗措施与生存率比较显示差异无明显性（Ｐ＞０．０５）。结论ＭＡＬＴ淋巴瘤是非霍奇金淋巴瘤的一种独特亚型，具有起病隐匿、病程长、进展慢及患病率低、好发于中老年男性、Ｂ症状少见、易误诊为假性淋巴瘤、治疗疗效和预后良好等特征。
Objective To improve the understanding of the clinical features of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Methods 24 cases of MALT lymphoma diagnosed in our hospital were retrospectively analyzed. The results can be divided according to the primary site of gastrointestinal (GI) and non-gastrointestinal (NON-GI) two groups. In the GI group, 18 cases (75%), NON-GI group (6 cases, 25.0%), and the latter included 3 cases of parotid gland, 2 cases of lung, and 1 case of bladder. Surgical treatment was performed in 21 cases, of which 13 cases were treated with surgery alone, 7 cases were treated with combined chemotherapy and radiotherapy, and 1 case was treated with radiation therapy. Only chemotherapy was used in 3 cases. Seventeen patients were followed up and 7 were lost. The follow-up rate was 70.8%. The survival period was 4 to 121 months, with an average of 33 months and a median of 19 months. Among the 17 patients followed up, 16 cases had survived for 1 to 10 years, among whom 58.8% survived for more than 1 year, 35.3% for >3 years, 29.4% for more than 5 years, and more than 10 years. Accounted for 5.9%. There was no significant difference between the clinical stage and treatment measures and survival rate (P>0.05). Conclusion MALT lymphoma is a unique subtype of non-Hodgkin’s lymphoma. It has onset, occult disease, long course, slow progress and low prevalence. It occurs in middle-aged and elderly men, B is rare, and is often misdiagnosed as pseudo-lymphoid. Tumor, treatment efficacy and good prognosis.